Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

NCT01720901 · clinicaltrials.gov ↗

PHASE4

Phase

SUSPENDED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Accrual limitations

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.